Role of Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy
2004; Lippincott Williams & Wilkins; Volume: 109; Issue: 4 Linguagem: Inglês
10.1161/01.cir.0000114144.40315.c0
ISSN1524-4539
AutoresCarey Kimmelstiel, Barry J. Maron,
Tópico(s)Cardiac pacing and defibrillation studies
ResumoHomeCirculationVol. 109, No. 4Role of Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBRole of Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy Carey D. Kimmelstiel and Barry J. Maron Carey D. KimmelstielCarey D. Kimmelstiel From the Hypertrophic Cardiomyopathy Center and Cardiac Catheterization Laboratory, Division of Cardiology, Tufts-New England Medical Center, Boston, Mass (C.D.K.), and The Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minn (B.J.M.). and Barry J. MaronBarry J. Maron From the Hypertrophic Cardiomyopathy Center and Cardiac Catheterization Laboratory, Division of Cardiology, Tufts-New England Medical Center, Boston, Mass (C.D.K.), and The Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minn (B.J.M.). Originally published3 Feb 2004https://doi.org/10.1161/01.CIR.0000114144.40315.C0Circulation. 2004;109:452–456Case Presentation: A 58-year-old diabetic man was referred for severe progressive exertional dyspnea consistent with New York Heart Association (NYHA) functional class III. Six years earlier, he underwent coronary artery bypass grafting, complicated by a sternal wound infection.Physical examination was notable for a bifid carotid pulse and loud apical systolic ejection murmur. Echocardiography documented hyperdynamic left ventricular (LV) systolic function and asymmetric hypertrophy confined to the basal ventricular septum (measuring 20 mm in thickness) consistent with hypertrophic cardiomyopathy (HCM). Continuous wave Doppler estimated a 65 mm Hg subaortic gradient due to dynamic systolic anterior motion of the mitral valve with septal contact. Coronary angiography showed patent bypass grafts.Medical management with β-blockers and verapamil was ineffective in controlling symptoms. Catheter-based intervention was considered for this patient to reduce outflow obstruction and symptoms.HCM is a relatively common genetic disease with important clinical consequences, including sudden death in the young and disability due to heart failure at any age.1,2 It is estimated that progression to NYHA functional classes III/IV associated with obstruction to LV outflow occurs in about 10% of HCM patients who are limited largely by exertional dyspnea, chest pain, fatigue, and occasionally orthopnea or nocturnal dyspnea.1,2 Long-term consequences of HCM attributable to outflow obstruction have been emphasized, particularly progression of disabling symptoms and death related to heart failure.2Therapeutic Options in Obstructive HCMThe traditional first line of therapy to improve quality of life in HCM patients with symptoms and outflow obstruction has been administration of negative inotropic agents, including β-blockers, verapamil, and disopyramide.1,2 Although symptoms can be controlled by drug treatment, a small minority of patients may become disabled and refractory to maximum medical management, and consequently eligible for major therapeutic interventions that target relief of obstruction and mitral regurgitation.1 Historically, this strategy has been confined to the "gold-standard" ventricular septal myectomy operation,1 and substantial benefit has been attributed to this procedure over the past 45 years throughout the world.1,2However, experience with surgery has been limited to a relatively small number of centers in North America and Europe.1 Many countries with large numbers of HCM patients do not have ready access to such surgical expertise, and some patients are not optimal candidates for operation. Therefore, alternative therapeutic options for surgical candidates with HCM have justifiably been pursued.1,3There has been considerable interest over the past few years in a percutaneous method for relieving obstruction and symptoms that has been referred to in the literature by several names and acronyms.3–9 This procedure uses conventional interventional methodology currently available for treating atherosclerotic coronary artery disease to create necrosis of the anterior basal septum by introducing absolute alcohol directly into a proximal septal perforator artery, ultimately reducing LV wall thickness, enlarging the outflow tract and reducing mechanical impedance to LV ejection. Therefore, percutaneous transluminal septal myocardial ablation (PTSMA) may mimic the morphological and hemodynamic effects of surgical myectomy.PTSMA TechniqueThe presence or absence of significant epicardial coronary artery disease, particularly in the left anterior descending (LAD) coronary artery, is documented by angiography. The baseline gradient is measured by use of an end-hole pigtail catheter, assuring that the level of obstruction is subaortic. For patients in whom the outflow gradient is either absent or small under the basal conditions, the magnitude of provocable obstruction is most appropriately assessed with physiological exercise.Of particular importance is proper selection of the target septal perforator. The optimal method is unresolved; some operators favor a pressure and fluoroscopic-guided technique in which balloon occlusion of the septal artery is followed by fluoroscopy to identify proximal septal tissue that is the target for ablation.4 Most other PTSMA practitioners utilize myocardial contrast echocardiography to identify the appropriate septal perforator, which involves 2-dimensional echocardiographic monitoring during introduction of 1 to 2 mL of echo or angiographic contrast through the distal lumen of a balloon dilation catheter.5,6 Contrast echocardiography enhances the effectiveness and safety of PTSMA by avoiding arteries that supply distant regions of myocardium, as well as by limiting the number of arteries intervened, the frequency of complete heart block requiring permanent pacemaker, the amount of alcohol injected (and creatine phosphokinase levels), and fluoroscopy time. After identification of the most appropriate perforator, balloon occlusion is followed by contrast injection through the coronary guide catheter as well as the distal balloon port to document complete cessation of flow between the distal septal artery and LAD.PTSMA is performed by injection of 1 to 4 mL of 96% to 98% ethanol into the target artery in 0.5 to 1.0 mL aliquots at 1 mL/min (Figure 1). Reduced amounts of ethanol and slower infusion minimizes complications, particularly high grade atrioventricular block.2,4–9 In the laboratory, the goal of PTSMA is acute reduction in resting and/or provoked gradient by 50% or to <20 mm Hg. The immediate post-ablation gradient reduction is probably due to alcohol-mediated septal necrosis and stunning, a mechanism distinct from the septal thinning and ventricular remodeling that is associated with progressive gradient reduction on long-term follow-up.5–9Download figureDownload PowerPointFigure 1. A, Pre-ablation. Coronary angiogram showing 2 septal perforators (arrow and arrowhead) in close proximity. Myocardial contrast echocardiography demonstrated that the first septal perforator artery (arrow) was the optimal vessel for alcohol injection. B, Pre-ablation. Baseline hemodynamics showing 110 mm Hg subaortic gradient. Post-extrasystolic beat (*) augmentation of gradient (to180 mm Hg) in association with "spike and dome" (Brockenbrough) aortic waveform. Scale: 0 to 280 mm Hg. C, Post-ablation. Angiogram shows the first septal perforator (arrow) is ablated. D, Post-ablation. Marked reduction in outflow gradient to 25 mm Hg. Ao indicates aorta; PA, pulmonary artery; and LV, left ventricle.Clinical ResultsPTSMA has not been subjected to randomized clinical trials against the septal myectomy in patients with severe symptoms and outflow obstruction. However, observational data from US and European centers over short follow-up periods are reasonably consistent, attributing a number of favorable effects to PTSMA that generally parallel that of surgery, including gradual and progressive reduction in outflow gradient over 3 to 12 months and alleviation of symptoms.4–6In a comparative non-randomized study at 2 independent institutions, myectomy and alcohol ablation showed a similar degree of gradient reduction.5 Another comparative analysis from a single institution showed both surgery and PTSMA to substantially reduce outflow gradients, but to a greater degree with surgery.7 A third nonrandomized study showed surgery and PTSMA to afford similar benefit in reducing LV outflow gradient, both acutely and after 1 year; however, surgical myectomy out-performed PTSMA with respect to improvement in exercise capacity.8 Patients with predominant provocable obstruction may also benefit from PTSMA.9Although reports of symptomatic benefit after PTSMA have been based largely on retrospective and uncontrolled assessments, some objective data are now available describing clinical improvement in terms of measured exercise capacity by treadmill exercise time and peak oxygen consumption. Significant and progressive enhancement in exercise treadmill time or maximum workload or peak oxygen consumption have been reported to be associated with gradient reduction in follow-up studies over 3 to 18 months.4,6–9ComplicationsComplication rates after PTSMA have declined since the initial reports because of evolution of the "learning curve" for operators. Specifically, there is greater appreciation for identifying the most appropriate septal vessel for intervention (Figure 1 and Figure 2) and using smaller amounts of alcohol (introduced more slowly) creating more limited areas of myocardial necrosis and scarring.4,6,10 PTSMA-related mortality has been reported at up to 4%, but in experienced centers is currently 1% to 2% (similar to that of surgery).7–9 Conduction abnormalities are relatively common complications of PTSMA, with permanent right bundle branch block and transitory heart block in about 50% and high-grade atrioventricular block requiring permanent pacemakers in 5% to 20%. Particular concern regarding complete heart block relates to its occasional unheralded occurrence after PTSMA, mandating inpatient monitoring for 4 to 5 days. A profound complication is anterior myocardial infarction due to ethanol reflux from the septal perforator down the LAD, avoidable by scrupulous balloon positioning. Other rare complications include coronary dissection, perforation, and thrombosis. Download figureDownload PowerPointFigure 2. Long-axis echocardiogram after PTSMA. Because of inappropriate selection of the septal perforator for alcohol injection and ablation, septal thinning developed distal to site of systolic anterior motion (single arrow). Consequently, the patient experienced persistent LV outflow obstruction due to mitral-septal contact (double arrows) and continued limitation from heart failure symptoms. RV indicates right ventricle; VS, ventricular septum; and LA, left atrium.Selection of Patients for PTSMASelection of patients for PTSMA (Figure 3) includes those with severe symptoms (ie, NYHA functional classes III or IV) refractory to maximal medical management associated with a LV outflow gradient ≥50 mm Hg at rest or after provocation (with physiological exercise) and basal septal thickness ≥18 mm, particularly if such patients have advanced age, with important co-morbidity or contraindications, or with insufficient motivation for surgery. Selected obstructed patients in advanced functional class II may be eligible for intervention, such as when symptoms interfere with their occupation. Dobutamine, an inotropic and catecholamine-inducing drug, and powerful stimulant of subaortic gradients in normal hearts or cardiac diseases other than HCM, is not recommended to provoke LV outflow gradients to assess the appropriateness of PTSMA in HCM.1,3 PTSMA is not indicated in the nonobstructive form of HCM. Download figureDownload PowerPointFigure 3. Proposed contemporary treatment algorithm for obstructive HCM. AV indicates atrioventricular.However, patients with congenital anomalies of the mitral valve apparatus, unfavorable distribution of septal hypertrophy with mild proximal thickening, associated heart lesions requiring surgical correction, or anatomically unsuitable septal perforators should not undergo PTSMA.1Limitations and Unresolved IssuesAlthough PTSMA has found a place in the therapeutic armamentarium of HCM, several important considerations persist. The first issue concerns the potential long-term consequences of the intramyocardial septal scar (often transmural) intentionally produced by PTSMA (and which is not a consequence of septal myectomy).1,3 Even before PTSMA, patients may already harbor an electrically unstable myocardial substrate prone to reentrant ventricular arrhythmias. This raises the reasonable possibility that the resultant septal infarct could enhance (but certainly not reduce) likelihood of sudden death in some patients. There are, however, practical difficulties in assessing this potential complication of PTSMA, given the short follow-up period (ie, < 5 years) currently available for the vast majority of patients, as well as the particularly long risk period implicit in young HCM patients. The vast numbers of patients treated with PTSMA, scattered among many small centers and practices, make it difficult to assemble precise long-term follow-up data and discern whether inevitable sudden deaths are a consequence of PTSMA or underlying HCM.It is counterintuitive to promote PTSMA as a treatment intervention to reduce risk for sudden death in HCM. Therefore, it is most prudent to discourage PTSMA in young adults (and especially children) when the surgical option is available, given the long (essentially lifetime) risk period for arrhythmia-mediated sudden death, at least until more data regarding the long-term consequences of PTSMA are available. Indeed, there is a strong preference in HCM centers experienced with both procedures to refer younger patients for septal myectomy.1,8 Randomized trials of PTSMA versus surgery are unlikely to clarify the issue of late post-procedural clinical events because of practical obstacles in designing studies of sufficient duration to encompass the substantial period of risk.A second major area of concern is the large number of PTSMA procedures performed over a relatively short period of time, unavoidably suggesting a lower threshold in recommending this procedure than for surgery. There have been an estimated 3000 PTSMA procedures performed worldwide in just 5 years. Therefore, PTSMA has probably been performed at a rate of 10 to 30 times that of surgery during this time, and has probably already surpassed the number of septal myectomies performed during the past 40 years. This suggests that many patients have undergone PTSMA before achieving the same symptom (and gradient) threshold advocated for surgical intervention. Part of this enthusiasm for PTSMA derives understandably from the relative ease with which PTSMA can be performed compared with surgery, involving shorter postoperative recovery and less discomfort. However, it should be underscored that even in experienced hands, PTSMA may incur morbidity and mortality similar to that of septal myectomy.ConclusionsThe HCM patient presented here experienced severe disabling symptoms (refractory to medical management), judged to be due to marked LV outflow obstruction. His prior bypass surgery (and postoperative complications) made him an undesirable candidate for septal myectomy. He accepted the PTSMA option and 1.5cc of alcohol were infused into a proximal septal perforator, resulting in a peak creatine phosphokinase of 750U/L. There were no complications other than transient complete heart block requiring temporary pacing for 2 days; he was discharged 5 days after ablation. Six months later, a substantial reduction in outflow gradient (from 65 to 10 mm Hg) was evident, and he became virtually asymptomatic. The patient is being monitored at regular intervals for changes in symptoms, outflow gradient, and arrhythmias. Such cases support the benefit of PTSMA in selected patients with obstructive HCM.FootnotesCorrespondence to Carey D. Kimmelstiel, MD, Tufts-New England Medical Center, 750 Washington St, Boston, MA 02111-5913. E-mail [email protected] References 1 Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2003; 42: 1687–1713.CrossrefMedlineGoogle Scholar2 Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003; 348: 295–303.CrossrefMedlineGoogle Scholar3 Maron BJ. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet. 2000; 355: 425–426.CrossrefMedlineGoogle Scholar4 Boekstegers P, Steinbigler P, Molnar A, et al. Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001; 38: 846–853.CrossrefMedlineGoogle Scholar5 Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2001; 38: 1701–1706.CrossrefMedlineGoogle Scholar6 Faber L, Meissner A, Ziemssen P, et al. Percutaneous transluminal septal myocardial ablation for hypertrophic cardiomyopathy. Heart. 2000; 83: 326–331.CrossrefMedlineGoogle Scholar7 Qin JX, Shiota T, Lever HM, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol. 2001; 38: 1994–2000.CrossrefMedlineGoogle Scholar8 Firoozi S, Elliott PM, Sharma S, et al. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic cardiomyopathy. Eur Heart J. 2002; 23: 1617–1624.CrossrefMedlineGoogle Scholar9 Gietzen FH, Leuner CJ, Obergassel L, et al. Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, NYHA functional class III-IV, and outflow tract obstruction only under provocable conditions. Circulation. 2002; 106: 454–459.LinkGoogle Scholar10 Mayer SA, Anwar A, Grayburn PA. Comparison of successful and failed alcohol septal ablations for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2003; 92: 241–242.CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Kimmelstiel C (2022) Alcohol Septal Ablation Cardiology Procedures, 10.1007/978-3-030-95259-4_34, (275-280), . Nakano T, Takahashi T, Yamamoto C, Kaji T and Fujiwara Y (2021) Arsenite induces tissue factor synthesis through Nrf2 activation in cultured human aortic smooth muscle cells, The Journal of Toxicological Sciences, 10.2131/jts.46.187, 46:4, (187-192), . Vermaete I, Dujardin K and Stammen F (2019) Looking back on 15 years of ultrasound-guided alcohol septal ablation for hypertrophic obstructive cardiomyopathy, Acta Cardiologica, 10.1080/00015385.2019.1626550, 75:6, (483-491), Online publication date: 1-Nov-2020. Bokeria L, Egorov D, Popov A, Bledzhyants G, Artyukhina T and Movsesyan R (2020) Effectiveness of Bokeria—Boldyrev ACH Solution in Surgerical Treatment of Adult Patients with Obstructive Hypertrophic Cardiomyopathy, Bulletin of Experimental Biology and Medicine, 10.1007/s10517-020-04878-7, 169:3, (318-323), Online publication date: 1-Jul-2020. Paranal R, Teekakirikul P, Ho C, Fatkin D and Seidman C (2020) Genetic Cardiomyopathies Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics, 10.1016/B978-0-12-812532-8.00002-1, (77-114), . Colan S and Miliaresis C (2019) Pediatric Diagnosis and Management Hypertrophic Cardiomyopathy, 10.1007/978-3-319-92423-6_9, (121-144), . Cooper R and Stables R (2017) Non-surgical septal reduction therapy in hypertrophic cardiomyopathy, Heart, 10.1136/heartjnl-2016-309952, 104:1, (73-83), Online publication date: 1-Jan-2018. Faber L (2018) Hypertrophic Cardiomyopathy Cardiology Secrets, 10.1016/B978-0-323-47870-0.00024-6, (216-223), . Bos J and Ackerman M (2018) Hypertrophic Cardiomyopathy in the Era of Genomic Medicine Genomic and Precision Medicine, 10.1016/B978-0-12-801812-5.00005-6, (103-126), . Kimmelstiel C (2017) Alcohol Septal Ablation Cardiology Procedures, 10.1007/978-1-4471-7290-1_31, (275-282), . Cooper R, Shahzad A and Stables R (2015) Intervention in HCM: patient selection, procedural approach and emerging techniques in alcohol septal ablation, Echo Research & Practice, 10.1530/ERP-14-0058, 2:1, (R25-R35), Online publication date: 1-Mar-2015. Colan S (2015) Pediatric Diagnosis and Management Hypertrophic Cardiomyopathy, 10.1007/978-1-4471-4956-9_9, (107-122), . Enriquez A and Goldman M (2014) Management of Hypertrophic Cardiomyopathy, Annals of Global Health, 10.1016/j.aogh.2013.12.004, 80:1, (35) Cunningham L and Ramasubbu K (2014) Hypertrophic Cardiomyopathy Cardiology Secrets, 10.1016/B978-1-4557-4815-0.00027-1, (203-210), . Cooper R, Shahzad A and Stables R (2013) Current status of nonsurgical septal reduction therapy in hypertrophic obstructive cardiomyopathy, Interventional Cardiology, 10.2217/ica.13.33, 5:4, (427-439), Online publication date: 1-Aug-2013. Teekakirikul P, Ho C and Seidman C (2013) Inherited Cardiomyopathies Emery and Rimoin's Principles and Practice of Medical Genetics, 10.1016/B978-0-12-383834-6.00053-7, (1-38), . Bos J, Ommen S and Ackerman M (2013) Hypertrophic Cardiomyopathies Genomic and Personalized Medicine, 10.1016/B978-0-12-382227-7.00050-1, (572-586), . Sorajja P, Binder J, Nishimura R, Holmes D, Rihal C, Gersh B, Bresnahan J and Ommen S (2012) Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy, Catheterization and Cardiovascular Interventions, 10.1002/ccd.24328, 81:1, (E58-E67), Online publication date: 1-Jan-2013. Maron B (2012) Commentary and Re-Appraisal: Surgical Septal Myectomy Vs. Alcohol Ablation: After a Decade of Controversy and Mismatch Between Clinical Practice and Guidelines, Progress in Cardiovascular Diseases, 10.1016/j.pcad.2012.04.008, 54:6, (523-528), Online publication date: 1-May-2012. Veselka J, Tomašov P and Zemánek D (2011) Long-Term Effects of Varying Alcohol Dosing in Percutaneous Septal Ablation for Obstructive Hypertrophic Cardiomyopathy: A Randomized Study With a Follow-up up to 11 Years, Canadian Journal of Cardiology, 10.1016/j.cjca.2011.09.001, 27:6, (763-767), Online publication date: 1-Nov-2011. Faber L, Prinz C, Welge D, Hering D, Butz T, Oldenburg O, Bogunovic N and Horstkotte D (2010) Peak systolic longitudinal strain of the lateral left ventricular wall improves after septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: a follow-up study using speckle tracking echocardiography, The International Journal of Cardiovascular Imaging, 10.1007/s10554-010-9678-0, 27:3, (325-333), Online publication date: 1-Mar-2011. Rigopoulos A and Seggewiss H (2011) A Decade of Percutaneous Septal Ablation in Hypertrophic Cardiomyopathy, Circulation Journal, 10.1253/circj.CJ-10-0962, 75:1, (28-37), . Colan S (2011) Treatment of hypertrophic cardiomyopathy in childhood, Progress in Pediatric Cardiology, 10.1016/j.ppedcard.2010.11.004, 31:1, (13-19), Online publication date: 1-Jan-2011. Tuggle D (2010) Hypotension and shock, Nursing, 10.1097/01.NURSE.0000388707.75684.71, 40, (1-5), Online publication date: 1-Oct-2010. Colan S (2010) Hypertrophic Cardiomyopathy in Childhood, Heart Failure Clinics, 10.1016/j.hfc.2010.05.004, 6:4, (433-444), Online publication date: 1-Oct-2010. Silva R, Skimming J and Muniz R (2010) Cardiovascular Safety of Stimulant Medications for Pediatric Attention-Deficit Hyperactivity Disorder, Clinical Pediatrics, 10.1177/0009922810368289, 49:9, (840-851), Online publication date: 1-Sep-2010. Kimmelstiel C (2010) Reducing arrhythmic complications following alcohol septal ablation-The utility of lower doses of ethanol, Catheterization and Cardiovascular Interventions, 10.1002/ccd.22487, 75:4, (551-552), Online publication date: 1-Mar-2010. Hess O and Streit S (2010) Alcohol Ablation of Hypertrophic Cardiomyopathy Current Best Practice in Interventional Cardiology, 10.1002/9781444314441.ch9, (117-125) Yao D and Ramasubbu K (2010) Hypertrophic Cardiomyopathy Cardiology Secrets, 10.1016/B978-032304525-4.00029-0, (196-202), . Martijn Bos J, Ommen S and Ackerman M (2010) Genetics and Genomics of Hypertrophic Cardiomyopathy Essentials of Genomic and Personalized Medicine, 10.1016/B978-0-12-374934-5.00028-3, (336-349), . Marian A (2010) Hypertrophic Cardiomyopathy Clinical Approach to Sudden Cardiac Death Syndromes, 10.1007/978-1-84882-927-5_16, (191-201), . Maron B (2009) Sudden Death in Hypertrophic Cardiomyopathy, Journal of Cardiovascular Translational Research, 10.1007/s12265-009-9147-0, 2:4, (368-380), Online publication date: 1-Dec-2009. Tuggle D (2009) Hypotension & shock, Nursing Critical Care, 10.1097/01.CCN.0000363760.78754.fa, 4:6, (28-35), Online publication date: 1-Nov-2009. Kelley-Hedgepeth A and Maron M (2009) Imaging techniques in the evaluation and management of hypertrophic cardiomyopathy, Current Heart Failure Reports, 10.1007/s11897-009-0020-x, 6:3, (135-141), Online publication date: 1-Sep-2009. Silvestry F, Kerber R, Brook M, Carroll J, Eberman K, Goldstein S, Herrmann H, Homma S, Mehran R, Packer D, Parisi A, Pulerwitz T, Seward J, Tsang T and Wood M (2009) Echocardiography-Guided Interventions, Journal of the American Society of Echocardiography, 10.1016/j.echo.2008.12.013, 22:3, (213-231), Online publication date: 1-Mar-2009. Bos J, Ommen S and Ackerman M (2009) Vaccines Genomic and Personalized Medicine, 10.1016/B978-0-12-369420-1.00061-5, (716-728), . Whitten S (2008) Systolic Heart Failure in a Patient With Hypertrophic Obstructive Cardiomyopathy, Critical Care Nurse, 10.4037/ccn2008.28.5.44, 28:5, (44-52), Online publication date: 1-Oct-2008. MARON B and SPIRITO P (2008) Implantable Defibrillators and Prevention of Sudden Death in Hypertrophic Cardiomyopathy, Journal of Cardiovascular Electrophysiology, 10.1111/j.1540-8167.2008.01147.x, 19:10, (1118-1126), Online publication date: 1-Oct-2008. Garg P and Walton A (2008) The New World of Cardiac Interventions: A Brief Review of the Recent Advances in Non-Coronary Percutaneous Interventions, Heart, Lung and Circulation, 10.1016/j.hlc.2007.10.019, 17:3, (186-199), Online publication date: 1-Jun-2008. Maron B, Ommen S, Nishimura R and Dearani J (2008) Myths About Surgical Myectomy: Rumors of Its Death Have Been Greatly Exaggerated, The American Journal of Cardiology, 10.1016/j.amjcard.2007.10.055, 101:6, (887-889), Online publication date: 1-Mar-2008. SEIDEL A, KAPADIA S, LEVER H and TUZCU E (2008) Septal ablation for HCM Essential Interventional Cardiology, 10.1016/B978-0-7020-2981-3.50038-6, (469-480), . Faber L, Welge D, Fassbender D, Schmidt H, Horstkotte D and Seggewiss H (2007) One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response, Clinical Research in Cardiology, 10.1007/s00392-007-0578-9, 96:12, (864-873), Online publication date: 1-Dec-2007. Amano Y, Takayama M, Kumita S and Kumazaki T (2007) MR Imaging Evaluation of Regional, Remote, and Global Effects of Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy, Journal of Computer Assisted Tomography, 10.1097/rct.0b013e31803151fd, 31:4, (600-604), Online publication date: 1-Jul-2007. Joyal D, Arab D, Chen-Johnston C and Leya F (2007) Alcohol septal ablation after failed surgical myectomy, Catheterization and Cardiovascular Interventions, 10.1002/ccd.21165, 69:7, (999-1002), Online publication date: 1-Jun-2007. Zhu T, Yang Z, Wang L, Wang H, Cao K, Huang J and Ma W (2007) Acute and mid-term results of pecutaneous transluminal septal myocardial ablation in patients with hypertrophic obstructive cardiomyopathy, Journal of Nanjing Medical University, 10.1016/S1007-4376(07)60034-3, 21:3, (143-146), Online publication date: 1-Apr-2007. Subash Chandra V, Jayranganth M and Shenoy A (2006) Non-surgical septal reduction for hypertrophic cardiomyopathy in childhood, International Journal of Cardiology, 10.1016/j.ijcard.2005.02.009, 106:3, (355-359), Online publication date: 1-Jan-2006. COLAN S (2006) Cardiomyopathies Nadas' Pediatric Cardiology, 10.1016/B978-1-4160-2390-6.50031-3, (415-458), . Faber L, Seggewiss H, Gietzen F, Kuhn H, Boekstegers P, Neuhaus† L, Seipel L and Horstkotte D (2005) Catheter-based septalablation for symptomatic hypertrophic obstructive cardiomyopathy:Katheter-basierte Septumablation bei symptomatischer hypertropher obstruktiver Kardiomyopathie: Follow-up—Ergebnisse des TASH-Registers der Deutschen Gesellschaft für Kardiologie, Zeitschrift für Kardiologie, 10.1007/s00392-005-0256-8, 94:8, (516-523), Online publication date: 1-Aug-2005. Cheng T (2005) Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: How much alcohol should be injected?, Catheterization and Cardiovascular Interventions, 10.1002/ccd.20384, 65:2, (313-314), Online publication date: 1-Jun-2005. Lee J, Moon J, Pennell D, Sigwart U and Clague J (2005) Late recurrence of outflow tract obstruction seven years after septal ablation in hypertrophic cardiomyopathy, International Journal of Cardiology, 10.1016/j.ijcard.2005.01.002, 100:2, (341-342), Online publication date: 1-Apr-2005. Ralph-Edwards A, Woo A, McCrindle B, Shapero J, Schwartz L, Rakowski H, Wigle E and Williams W (2005) Hypertrophic obstructive cardiomyopathy: Comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score, The Journal of Thoracic and Cardiovascular Surgery, 10.1016/j.jtcvs.2004.08.047, 129:2, (351-358), Online publication date: 1-Feb-2005. Maron B, Dearani J, Ommen S, Maron M, Schaff H, Gersh B and Nishimura R (2004) The case for surgery in obstructive hypertrophic cardiomyopathy, Journal of the American College of Cardiology, 10.1016/j.jacc.2004.04.063, 44:10, (2044-2053), Online publication date: 1-Nov-2004. Boltwood C, Chien W and Ports T (2004) Ventricular Tachycardia Complicating Alcohol Septal Ablation, New England Journal of Medicine, 10.1056/NEJM200410283511824, 351:18, (1914-1915), Online publication date: 28-Oct-2004. Maron B (2004) Hypertrophic cardiomyopathy in childhood, Pediatric Clinics of North America, 10.1016/j.pcl.2004.04.017, 51:5, (1305-1346), Online publication date: 1-Oct-2004. Cheng T (2004) In Percutaneous Transluminal Septal Myocardial Ablation for Hypertrophic Obstructive Cardiomyopathy, It Is Not the Speed of Intracoronary Alcohol Injection But the Amount of Alcohol Injected That Determines the Resultant Infarct Size, Circulation, 110:3, (e23-e23), Online publication date: 20-Jul-2004. Monakier D, Woo A, Vannan M and Rakowski H (2004) Myocardial contrast echocardiography in chronic ischemic and nonischemic cardiomyopathies, Cardiology Clinics, 10.1016/j.ccl.2004.03.001, 22:2, (269-282), Online publication date: 1-May-2004. February 3, 2004Vol 109, Issue 4 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000114144.40315.C0PMID: 14757682 Originally publishedFebruary 3, 2004 PDF download Advertisement
Referência(s)